Related Experiment Video
Updated: Dec 9, 2025

Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
QTc Prolongation in Pediatric Patients with Diabetic Ketoacidosis
Michelle M Perez1, Shivanand Medar2, Leanne Quigley3
1Division of Pediatric Critical Care, Children's Hospital at Montefiore, Bronx, NY.
Insights
Diabetic ketoacidosis (DKA) in children is linked to prolonged QTc intervals, with severity correlating to the degree of prolongation. This finding highlights potential cardiac risks in pediatric DKA patients.
Area of Science:
- Pediatric Cardiology
- Endocrinology
- Clinical Electrophysiology
Background:
- Diabetic ketoacidosis (DKA) is a serious complication of diabetes mellitus.
- QTc interval prolongation is a risk factor for cardiac arrhythmias.
Purpose of the Study:
- To investigate the association between DKA and QTc interval prolongation in pediatric patients.
- To assess the correlation between DKA severity and QTc prolongation.
Main Methods:
- Retrospective observational study of 96 pediatric patients admitted with DKA.
- Electrocardiograms (ECGs) were analyzed for QTc interval using Bazett's formula.
- DKA severity was classified based on pH levels; patients on QTc-prolonging medications were excluded.
Main Results:
- Mean QTc interval in DKA patients was 454 ± 32 msec.
- Significant differences in QTc intervals were observed across DKA severity groups (P = .05).
- Higher anion gaps were significantly associated with longer QTc intervals (r = 0.21, P = .04).
Conclusions:
- Thirty-one percent of pediatric DKA patients exhibited QTc prolongation.
- DKA severity and worsening acidosis are associated with increased QTc prolongation.
- Further research is needed to determine the clinical implications of these findings.
Objective:
To investigate the association between diabetic ketoacidosis (DKA) and prolonged QTc interval and to assess for correlation between DKA severity and QTc prolongation.
Study Design:
Retrospective observational study in a pediatric hospital. Patients admitted with DKA diagnosed by laboratory criteria and an electrocardiogram (ECG) performed during a period of acidosis were identified using Looking Glass Clinical Analytics. Data including age, sex, pH, electrolytes, anion gap, and ECG variables were collected. Patients were excluded if they had a prior diagnosis of prolonged QTc or were taking QTc prolonging medications. Severity of DKA was classified as mild (pH 7.24-7.3), moderate (pH 7-7.24), or severe (pH <7). ECGs were read by a pediatric electrophysiologist and QTc interval was manually calculated utilizing the Bazett formula.
Results:
Ninety-six patients were included (mean age 15.2 ± 4.2 years, pH 7.12 ± 0.12, bicarbonate 8.6 ± 3.7 mmol/L, potassium 5.3 ± 1.1 mEq/L). Mean QTc interval for all patients in DKA was 454 ± 32 msec. Mean QTc in the mild group was 441 ± 22 msec, moderate group 460 ± 36 msec, and severe group 461 ± 34 msec. There was a significant difference in QTc interval across DKA severity groups (P = .05). There was a significant association between higher anion gaps and greater QTc intervals (r = 0.21, P = .04).
Conclusions:
Thirty-one percent of pediatric patients with DKA demonstrated QTc prolongation on ECG. Severity of DKA and worsening acidosis were associated with increased prolongation of the QTc. Further study is required to evaluate the clinical impact of these findings.
More Related Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
08:28Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Depolarizing Blockers: Pharmocokinetics
Pharmacokinetics in Pediatric Patients: Drug Distribution
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers